New science chief at Bristol-Myers

|About: Bristol-Myers Squibb C... (BMY)|By:, SA News Editor

Aimed at getting buffing up its R&D pipeline, Bristol-Myers Squibb (NYSE:BMY) appoints Thomas Lynch as Chief Science Officer (CSO) replacing Francis Cuss.

Cuss, CSO since 2013, moved the company out of metabolic, neuroscience and virology drug discovery, decisions that have largely held up. Relying on growth from the crowded immuno-oncology space will be difficult, as evidenced by the recent missteps with top seller Opdivo.

Dr. Lynch is the former CEO of Massachusetts General Physicians Organization and has extensive experience treating and researching cancer.

Subscribe for full text news in your inbox